Pacira BioSciences, Inc. (PCRX) Stock Analysis
Momentum Cont setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Analyst target reached at $24.87 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak overall score: 4.8/10.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable... Read more
Sell if holding. Analyst target reached at $24.87 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak overall score: 4.8/10. Chart setup: Trend continuation, RSI 58, MACD bullish. Score 4.8/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.60, earnings proximity no date, semi cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $24.87 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak overall score: 4.8/10. Chart setup: Trend continuation, RSI 58, MACD bullish. Prior stop was $23.25. Score 4.8/10, moderate confidence.
Take-profit target: $25.23 (+0.9% upside). Prior stop was $23.25. Stop-loss: $23.25.
Analyst target reached - limited upside remaining; Weak overall score: 4.8/10; Weak growth.
Pacira BioSciences, Inc. trades at a P/E of 159.3 (forward 7.3). TrendMatrix value score: 7.0/10. Verdict: Sell.
13 analysts cover PCRX with a consensus score of 3.8/5. Average price target: $29.
What does Pacira BioSciences, Inc. do?Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain...
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.